The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis shows.
The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”.
Their vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.
The companies plan to apply for emergency approval to use the vaccine by the end of the month.
A vaccine – alongside better treatments – is seen as the best way of getting out of the restrictions that have been imposed on all our lives.
There are around a dozen in the final stages of testing – known as a phase 3 trial – but this is the first to show any results.
It uses a completely experimental approach – that involves injecting part of the virus’s genetic code – in order to train the immune system.
Previous trials have shown the vaccine trains the body to make both antibodies – and another part of the immune system called T-cells to fight the coronavirus.
Two doses, three weeks apart, are needed. The trials – in US, Germany, Brazil, Argentina, South Africa and Turkey – show 90% protection is achieved seven days after the second dose.
Pfizer believes it will be able to supply 50 million doses by the end of this year, and around 1.3 billion by the end of 2021.